SCHEMBL3973464

SCHEMBL3973464

O=C1CCCN1C1(c2cccc(F)c2)CCN(Cc2ccccc2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.48
CYP2D6 P10635 5/20 0.48
MAPK1 P28482 2/20 0.48
ALDH1A1 P00352 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
OPRL1 P41146 2/20 0.45
OPRM1 P35372 1/20 0.45
OPRD1 P41143 1/20 0.45
OPRK1 P41145 1/20 0.45
CHRM2 P08172 1/20 0.44
CHRM3 P20309 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
HPGD P15428 1/20 0.44
POLB P06746 1/20 0.43
TSHR P16473 2/20 0.43
RECQL P46063 1/20 0.42
SIGMAR1 Q99720 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27698325 0.86 OPRL1 (0.47) CYP2D6MAPK1OPRL1OPRM1OPRD1
SCHEMBL3896141 0.86 SIGMAR1 (0.50) BACE1CYP2D6MAPK1ALDH1A1OPRL1
SCHEMBL3899999 0.86 OPRL1 (0.45) BACE1CYP2D6MAPK1OPRL1OPRM1
SCHEMBL3908033 0.82 CYP2D6 (0.47) BACE1CYP2D6MAPK1ALDH1A1SMN1; SMN2
SCHEMBL27698386 0.81 OPRL1 (0.46) CYP2D6MAPK1OPRL1OPRM1OPRD1
SCHEMBL3905409 0.80 LMNA (0.51) CYP2D6MAPK1ALDH1A1SMN1; SMN2OPRL1
SCHEMBL3910153 0.78 OPRM1 (0.40) CYP2D6ALDH1A1SMN1; SMN2OPRL1OPRM1
SCHEMBL3899843 0.77 LMNA (0.54) CYP2D6MAPK1ALDH1A1SMN1; SMN2OPRL1
SCHEMBL3897579 0.75 CYP2D6 (0.53) CYP2D6MAPK1ALDH1A1SMN1; SMN2OPRL1
SCHEMBL3897322 0.75 OPRL1 (0.73) CYP2D6MAPK1ALDH1A1SMN1; SMN2OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773823-B1 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2013-08-21 EP disclosed
CN-101006084-B 4-arylmorpholin-3-one derivatives, preparation method and therapeutic use thereof SANOFI AVENTIS 2010-09-08 CN disclosed
US-7521449-B2 4-arylmorpholin-3-one derivatives, their preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2009-04-21 US disclosed
CN-101006084-A 4-arylmorpholin-3-one derivatives, preparation method and therapeutic use thereof SANOFI AVENTIS (FR) 2007-07-25 CN disclosed
US-20070142349-A1 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-06-21 US disclosed
EP-1773823-A1 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2007-04-18 EP disclosed
WO-2006021654-A1 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142349-A1 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF ADRB3, ADRA2C, OPRK1 BACE1 1083/4885CYP2D6 64/4885MAPK1 2502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.